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range prevents the progression of chronic kidney
disease in elderly chronic kidney disease patients
Eiichiro Kanda1,2*, Masumi Ai2, Masayuki Yoshida2, Renjiro Kuriyama3 and Tatsuo Shiigai4Abstract
Background: Metabolic acidosis leads to chronic kidney disease (CKD) progression. The guidelines recommend a
lower limit of serum bicarbonate level, but no upper limit. For serum bicarbonate level to be clinically useful as a
therapeutic target marker, it is necessary to investigate the target serum bicarbonate level within the normal range
to prevent CKD progression.
Methods: One hundred and thirteen elderly CKD patients, whose serum bicarbonate level was controlled within
the normal range, were enrolled in this retrospective cohort study in Ibaraki, Japan. Outcome was defined as a
decrease of 25% or more in estimated glomerular filtration rate (eGFR) or starting dialysis. We used Cox
proportional hazard models adjusted for patients’ characteristics to examine the association between serum
bicarbonate level and the outcome.
Results: Female patients were 36.3%: average age (SD), 70.4 (6.6) years; eGFR, 25.7 (13.6) ml/min/1.73 m2; serum
bicarbonate level, 27.4 (3.2) mEq/l. Patients with the lowest quartile of serum bicarbonate levels [23.4 (1.8) mEq/l]
showed a high risk of CKD progression compared with patients with high serum bicarbonate levels [28.8 (2.3) mEq/
l]: adjusted hazard ratio (HR), 3.511 (95% CI, 1.342-9.186). A 1 mEq/l increase in serum bicarbonate level was
associated with a low risk of CKD progression: adjusted HR, 0.791 [95% confidence interval (CI), 0.684-0.914].
Conclusions: In elderly CKD patients, our findings suggest that serum bicarbonate level is independently associated
with CKD progression, and that a high serum bicarbonate level is associated with a low risk of CKD progression. A
high target serum bicarbonate level within the normal range may be effective for preventing CKD progression.
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As the number of functioning nephrons decreases in
chronic kidney disease (CKD), total ammonium excre-
tion level begins to decrease when glomerular filtration
rate (GFR) is below 40 to 50 mL/min/1.73 m2 [1,2]. This
results in net retention of hydrogen ions and metabolic
acidosis [1,2]. Metabolic acidosis leads to CKD progres-
sion [3]. There is some evidence of the relationship be-
tween serum bicarbonate level and CKD progression.
Observational studies showed an association between a* Correspondence: tokyo.kyosai.kanda@gmail.com
1Department of Nephrology, Tokyo Kyosai Hospital, Nakameguro 2-3-8,
Meguroku, Tokyo 153-8934, Japan
2Tokyo Medical and Dental University, Bioethics Research Center, Yushima
1-5-45, Bunkyoku, Tokyo113-8519, Japan
Full list of author information is available at the end of the article
© 2013 Kanda et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orlow serum bicarbonate level and progression of kidney
diseases [4-7]. Intervention studies show that bicarbon-
ate supplementation slowed the progression of kidney
diseases [8-12].
Kidney function declines with histological changes of
the kidney with aging [13,14]. United States National
Health and Nutrition Examination Surveys showed that
a decreased GFR is associated with a high prevalence of
acidosis in elderly CKD patients [15]. Although elderly
CKD patients have a high risk of metabolic acidosis, we
were unable to find any reports about the effect of
serum bicarbonate level on CKD progression in elderly
CKD patients.
At present, the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (K/DOQI) guidelinestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(CARI) guidelines recommend that serum bicarbonate
level should be maintained at or above 22 mEq/l [16,17].
However, the guidelines recommend only this lower limit
of the target serum bicarbonate level, but no upper limit
in non-dialysis-dependent CKD patients. There have been
no confirmatory controlled trials on the therapeutic range
of serum bicarbonate levels. For serum bicarbonate level
to be clinically useful, in this retrospective cohort study of
elderly non-dialysis-dependent CKD patients whose
serum bicarbonate levels were controlled within the nor-
mal range, we evaluated the relationship between serum
bicarbonate level within the normal range and CKD pro-
gression, and investigated the upper limit of the target
serum bicarbonate level.
Subjects and methods
Study design and study population
This study was a retrospective cohort study of non-
dialysis-dependent CKD patients who were treated from
2009 to 2012 at Shiigai Clinic, Ibaraki, Japan. Patients
were eligible for inclusion in the sample for this study
when they were at least 60 years of age as of December
1st, 2009, diagnosed as having CKD on the basis of the
criteria of the Japanese Society of Nephrology, had an
estimated GFR (eGFR) of 60 ml/min/1.73 m2 or lower,
had never been treated by dialysis or undergone trans-
plantation, and their serum bicarbonate levels were
within the normal range (normal range, 21 to 32 mEq/l)
[18]. They usually visited the Shiigai Clinic once a month
[mean interval of visit and standard deviation (SD),
33.5 ± 3.0 days]. Patients who were treated for dementia,
lung diseases, chronic heart failure, or cancer were
excluded. We treated CKD as a general practice of the
clinic following the CKD practice guideline of the Japanese
Society of Nephrology [18]. A high serum bicarbonate
level was treated in accordance with K/DOQI guidelines
2000 [16]. Serum bicarbonate level was maintained from
22 to 32 mEq/l by administration of only sodium bi-
carbonate [16]. eGFR was calculated using the formula
adopted by the Japanese Society of Nephrology using
serum creatinine level [18]. This study was approved
by the Ethics Committee of Tokyo Kyosai Hospital,
Tokyo, Japan.
Data
The baseline characteristics of the population were re-
corded at the time of the patients’ initial evaluation in the
nephrology clinic. The patients’ demographics including
age, gender, and history of diabetes mellitus and hyper-
tension; laboratory variables, namely, albumin, sodium,
potassium, creatinine, bicarbonate, and urinary protein
levels; and the use of medications, namely, renin–angioten-
sin–aldosterone system (RAAS) inhibitors [angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor
blockers (ARBs) or direct renin inhibitors], loop diuretics,
and sodium bicarbonate were obtained from the medical
records of the patients treated at the clinic. Serum creatin-
ine level was recorded longitudinally every month. Routine
serum biochemistry was carried out by standard methods
at Shiigai Clinic. Serum bicarbonate level was measured by
an enzymatic carbonate method using a Dimension Xpand
analyzer (Siemens Healthcare Diagnostics Inc., Tokyo,
Japan). We defined the outcome as a decrease of 25% or
more in eGFR or starting hemodialysis or peritoneal dialy-
sis. The observation period was two years. The patients’
data were collected until they reached the outcome or
changed hospital. Data from patients who changed hospi-
tals were considered as censored observations.
Statistical analyses
Normally distributed variables are presented as mean ±
SD; otherwise, the median and interquartile range (IQR)
are presented. Intergroup comparisons were performed
using the chi-square test, t-test, and Mann–Whitney U-
test as appropriate. Univariate linear regression analysis
and multivariate linear regression analysis were carried
out to identify variables that were independently asso-
ciated with serum bicarbonate level by including factors
that were previously selected on the basis of p level in
univariate linear regression analysis (p level, 0.1 or
lower). Serum bicarbonate level was defined to be low
when it fell in the lower 25th percentile of serum bicar-
bonate level (25.5 mEq/l). Patients’ survival curves were
derived by Kaplan-Meier analysis. Cox proportional haz-
ard models were used to evaluate the relationship of
serum bicarbonate level with the outcome and to com-
pare the risk of the outcome between a group with a low
serum bicarbonate level (low-bicarbonate group) and the
group with a normal serum bicarbonate level (control
group). We adjusted several a priori-chosen covariates
sequentially. Model 2 was adjusted for patient demo-
graphics, namely, age, gender, diabetes, hypertension,
and body mass index (BMI); Model 3 was adjusted for
variables in model 2 and laboratory variables, namely,
eGFR, serum albumin, sodium, and potassium levels,
and 24-hour urine protein excretion level; Model 4 was
adjusted for variables in model 3 and variables for medi-
cations, namely, RAAS inhibitor use, loop diuretic use,
and sodium bicarbonate use. The results are presented
here as hazard ratios (HRs) with 95% confidence interval
(CI). Statistical significance was defined as p < 0.05.
These analyses were conducted using SAS, version 9.2
(SAS, Inc., Cary, North Carolina).
Results
One hundred and thirteen elderly CKD patients were
included in the sample for analysis. Patient demographics
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causes of CKD were as follows: diabetic nephropathy, 38
patients, 33.6%; chronic glomerulonephritis, 70 patients,
62.0%; and others, 5 patients, 4.4%. Within two years, 46
patients (40.7%) showed a decrease of 25% in their eGFR
and 10 patients (8.9%) started dialysis. Forty six patients
(40.7%) reached the outcome, and the rate of reaching the
outcome was 0.35 per patient-year. None of the patients
died. Thirty-three patients changed hospital (29.2%): low-




Age (years) 70.4 ± 6.6
Female (%) 41 (36.3)
Diabetes mellitus (%) 38 (33.6)
Hypertension (%) 45 (39.8)
Height (cm) 160.6 ± 8.9
Weight (kg) 58.3 ± 8.9
BMI (kg/m2) 22.5 ± 2.5





Albumin level (g/dl) 3.7 ± 0.3
Sodium level (mEq/l) 140.7 ± 2.3
Potassium level (mEq/l) 4.8 ± 0.5
Bicarbonate level (mEq/l) 27.4 ± 3.2
24-hour urine protein excretion level (g/day) 0.93 ± 1.01
0.52 (IQR, 0.25, 1.18)
RAAS inhibitor use (%) 98 (86.7)
ACEI use 51 (45.1)
ARB use 86 (76.1)
Direct renin inhibitor use 34 (30.4)
Loop diuretic use (%) 37 (32.7)
Sodium bicarbonate use (%) 23 (20.3)
Dose of sodium bicarbonate (g/day) 0.54 ± 1.29
0 (IQR, 0, 0)
Decrease of 25% or more in eGFR (%) 46 (40.7)
Dialysis (%) 10 (8.9)
Outcome (%) 46 (40.7)
Follow-up days (days) 449.3 ± 162.7
Values are expressed as mean ± standard deviation. The levels of 24-hour urine pro
IQR. The values are compared between the groups by the chi-square test, t-test, or
Abbreviations: BMI Body mass index, eGFR Estimated glomerular filtration rate, RAAS
inhibitor, ARB Angiotensin II receptor blocker, IQR Interquartile range; outcome, a dThe baseline characteristics of patients are shown in
Table 1. The low-bicarbonate group and control group
did not show significant differences in age, BMI, serum
albumin level, sodium level, and loop diuretic use. The
numbers of patients who were female, had diabetes, and
had hypertension were higher in the control group. The
low-bicarbonate group showed a lower eGFR, a higher
potassium level, a lower bicarbonate level, a higher 24-
hour urinary protein excretion level, a lower number of
RAAS inhibitor users, and a larger number of sodiumcarbonate level in comparison with those of
Low-bicarbonate group Control group p value
28 85
71.0 ± 6.9 70.2 ± 6.5 0.59
5 (17.9) 36 (42.4) 0.019
5 (17.9) 33 (38.8) 0.042
3 (10.7) 42 (49.4) 0.0003
164.8 ± 8.1 159.2 ± 8.7 0.005
60.9 ± 9.4 57.4 ± 8.6 0.08
22.3 ± 2.2 22.6 ± 2.5 0.61
15.1 ± 5.9 29.1 ± 13.6 0.0001
0.0001
1 (3.5) 39 (45.9)
12 (42.9) 32 (37.7)
15 (53.6) 14 (16.5)
3.7 ± 0.3 3.7 ± 0.4 0.99
140.9 ± 2.2 140.7 ± 2.4 0.63
5.0 ± 0.5 4.7 ± 0.5 0.004
23.4 ± 1.8 28.8 ± 2.3 0.0001
1.25 ± 1.19 0.83 ± 0.93 0.063
1.04 (IQR, 0.35, 1.66) 0.44 (IQR, 0.24, 1.11)
20 (71.4) 78 (91.8) 0.006
12 (42.9) 39 (45.9)
18 (64.3) 68 (80.0)
9 (32.1) 25 (29.8)
11 (39.3) 26 (30.6) 0.40
12 (42.9) 11 (12.9) 0.0006
1.28 ± 2.03 0.28 ± 0.78 0.0006
0 (IQR, 0, 2) 0 (IQR, 0, 0)
19 (67.9) 27 (31.8) 0.0007
6 (21.4) 4 (4.7) 0.007
19 (67.9) 27 (31.8) 0.0007
360.4 ± 184.6 478.6 ± 144.4 0.0007
tein excretion and dose of sodium bicarbonate are presented with median and
Mann–Whitney U-test as appropriate.
Renin angiotensin aldosterone system, ACEI Angiotensin-converting enzyme
ecrease of 25% or higher in eGFR or starting dialysis.
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sodium bicarbonate in the low-bicarbonate group was
from 0 to 9 g/day, and in the control group, from 0 to
4 g/day. The average dose of sodium bicarbonate in the
low-bicarbonate group was higher than that in the con-
trol group. A larger number of patients reached the out-
come in the low-bicarbonate group than in the control
group. The rates of reaching the outcome in the low-
bicarbonate group and control group were 0.69 and 0.24
per patient-year, respectively.
Baseline serum-bicarbonate-level-associated factors
There was a correlation between serum bicarbonate level
and the levels of other markers (Table 2). Serum bicar-
bonate level was positively associated with gender, dia-
betes, hypertension, and eGFR, and negatively with
potassium level, 24-hour urine protein excretion level,
and sodium bicarbonate use. Multivariate linear regres-
sion analysis of the variables associated with serum bi-
carbonate level in the univariate linear regression
analysis showed that bicarbonate level was independ-
ently associated with diabetes and eGFR.
Serum bicarbonate level and CKD progression
The Kaplan-Meier analysis showed a significant differ-
ence in the outcome among the groups (Log-rank test
p = 0.0005; Figure 1). The low-bicarbonate group was
associated with a high risk of the outcome after adjust-
ment for patient demographics, laboratory variables, and
relevant medications (Table 3). A 1 mEq/l increase in
serum bicarbonate level was associated with an 18.0%
lower risk of the outcome (Table 3). Analysis usingTable 2 Baseline serum bicarbonate level correlated with oth
Univariate linear regre
Difference in serum bicarbo
Age (years) −0.02
Female (%) 1.16




Albumin level (g/dl) 0.44
Sodium level (mEq/l) 0.23
Potassium level (mEq/l) −1.66
24-hour urine protein excretion level (g/day) −0.58
RAAS inhibitor (%) 1.59
Loop diuretic use (%) −0.64
Sodium bicarbonate use (%) −2.70
Values are expressed as differences in serum bicarbonate level (estimated paramete
diabetes, hypertension, eGFR, sodium level, potassium level, 24-hour urine protein e
Abbreviations: BMI Body mass index, eGFR Estimated glomerular filtration rate, RAAadjusted Cox proportional hazard models showed that
this relationship was consistent; adjusted HR 0.791 [95%
confidence interval (CI), 0.684-0.914] (Table 3).Discussion
In this study, the serum bicarbonate levels of the elderly
CKD patients were controlled within the normal range.
We demonstrated that a high serum bicarbonate level
was associated a low risk of CKD progression in elderly
CKD patients. Our findings are consistent with previous
reports that a low serum bicarbonate level is associated
with CKD progression [4-7,12]. There has been no study
of serum bicarbonate level in elderly CKD patients. The
participants in our present study were older than those
in other studies [11]. This study also showed that, al-
though the average serum bicarbonate level of the low-
bicarbonate group was controlled within the normal
range in accordance with K/DOQI guidelines 2000,
being in the lowest quartile of serum bicarbonate levels
was associated with a high risk of CKD progression. In
this analysis, a low serum bicarbonate level remained in-
dependently related to a high HR of CKD progression.
These findings suggest that a high serum bicarbonate
level within the normal range may prevent CKD pro-
gression in elderly CKD patients.
The optimal management of acidemia or metabolic
acidosis in CKD patients, including the monitoring of
serum bicarbonate level and sodium bicarbonate admin-
istration, has not been established yet. Our study showed
that the patients with a serum bicarbonate level lower
than 25.5 mEq/l had a high risk of CKD progression.
The K/DOQI guidelines 2000 and CARI guidelineser factors
ssion analysis Multiple linear regression analysis














r) and p values. Multiple linear regression analysis variables include gender,
xcretion level, and sodium bicarbonate use.
S Renin angiotensin aldosterone system.
Figure 1 Kaplan-Meier analysis of CKD-progression-free-survival in low-bicarbonate group compared with control group. The numbers
of patients at risk of the outcome are indicated beneath the graph. Abbreviations: CKD progression, reaching the outcome; Survival probability,
probability of being CKD-progression-free.
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be maintained at or above 22 mEq/l [16,17]. In a trial,
the effect of sodium bicarbonate on CKD progression
was compared between the bicarbonate-treated group
and the control group [8]. The average serum bicar-
bonate level of the control group at baseline was
19.9 mEq/l, and the average serum bicarbonate level of
the bicarbonate-treated group gradually became higher
than 22 mEq/l [8]. As the lower limit, 22 mEq/l may
be a useful target serum bicarbonate level in clinical
practice presently.
This study showed that a high serum bicarbonate level
within the normal range decreased the risk of CKD pro-
gression in elderly CKD patients. A subanalysis of the
African American Study of Kidney Disease and Hyper-
tension showed that a higher baseline serum bicarbonate
level within the range from 20 to 30 mEq/l was asso-
ciated with a lower risk of the composite of death, dialy-
sis, and GFR events [7]. A retrospective cohort study of
the Modification of Diet in Renal Disease Study showed
that patients with serum bicarbonate levels from 26 to
40 mEq/l had a lower risk of kidney failure or death than
patients with serum bicarbonate levels from 11 to
25 mEq/l [6]. However, the target serum bicarbonateTable 3 Hazard ratios for CKD progression according to basel
Model 1
Serum bicarbonate level (1 mEq/l increase) 0.820 (0.735, 0.915)
Low-bicarbonate group (ref. control group) 2.814 (1.539, 5.145)
Values are given as HRs (95% confidence interval). Adjusted variables in four Cox p
proportional hazard model; Model 2, adjusted for variables in model 1 and variable
hypertension, and BMI; Model 3, adjusted for variables in model 2 and variables ass
potassium levels, and 24-hour urine protein excretion level; Model 4, adjusted for v
namely, RAAS inhibitors, loop diuretics, and sodium bicarbonate.
Abbreviations: ref Reference, BMI Body mass index, eGFR Estimated glomerular filtralevel in the upper limit has not been established. A co-
hort study showed that patients with serum bicarbonate
levels higher than 32 mEq/l showed a higher risk of
death than patients with serum bicarbonate levels from
23 to 32 mEq/l [12]. The effect of a high serum bicar-
bonate level on mortality is related to complications
such as hypokalemia, hypocalcemia, or hypomagnes-
emia, with resultant cardiac arrhythmias [19]. These
studies suggest that, as long as serum bicarbonate level
is controlled within the normal range, a serum bicarbon-
ate level higher than the lower limit may reduce the risk
of CKD progression. Thus, the upper limit of the target
serum bicarbonate might be equal to the upper limit of
the normal range, 32 mEq/l.
It has been reported that the capacity to excrete net
endogenous acid decreases significantly with age [20].
Elderly CKD patients have a high risk of metabolic acid-
osis. It is necessary to regularly monitor their serum bi-
carbonate level to prevent metabolic acidosis. There has
been no report about the mechanisms that definitely ex-
plain CKD progression in response to metabolic acidosis
in not only elderly CKD patients but also young CKD
patients. From studies using animal models, a few
mechanisms are suggested. The increase in renaline characteristics
Model 2 Model 3 Model 4
0.816 (0.720, 0.924) 0.811 (0.700, 0.940) 0.791 (0.684, 0.914)
3.310 (1.570, 6.978) 2.514 (1.068, 5.918) 3.511 (1.342, 9.186)
roportional hazard models are as follows: Model 1, variables in univariate Cox
s associated with patient demographics, namely, age, gender, diabetes,
ociated with laboratory variables, namely, eGFR, serum albumin, sodium, and
ariables in model 3 and variables associated with the use of medications,
tion rate, RAAS Renin angiotensin aldosterone system.
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of ammonia production by metabolic acidosis activates
the alternative complement pathway and causes progres-
sive tubulointerstitial injury [21]. New bicarbonate synthe-
sized by the kidney in response to acidosis alkalinizes the
interstitium and promotes precipitation of calcium in the
kidney [22]. Increased endothelin production may mediate
the tubulointerstitial injury and decrease in GFR asso-
ciated with metabolic acidosis in CKD [10,23]. The mech-
anism underlying the renal protective effect of sodium
bicarbonate in humans has not been clarified yet, either.
Studies using experimental animal models of CKD suggest
that alkali therapy attenuates tubulointerstitial inflamma-
tion and may slow the progression to kidney failure
[21,24]. A cohort study of the African American Study of
Kidney Disease and Hypertension showed that net en-
dogenous acid production was associated with faster CKD
progression in CKD patients, whose serum bicarbonate
levels were within the normal range [25]. The present
study showed that a low serum bicarbonate level within
the normal range was independently related to a high HR
of CKD progression. These results suggest that a lower
serum bicarbonate level might indicate a higher net pro-
duction of endogenous or exogenous acids, which might
be the main cause of CKD progression. The administra-
tion of sodium bicarbonate to attain an upper limit of
serum bicarbonate level within the normal range may sup-
press CKD progression caused by net endogenous acid
production, and may prevent the subsequent events such
as interstitial fibrosis that lead to CKD progression.
This study has several limitations. First, as with any ob-
servational study, we were unable to compare two groups
whose characteristics were controlled. The patient distribu-
tion in CKD stages was not balanced, which might have
affected the results on the CKD progression in the low-
bicarbonate group. Nonetheless, this study showed that
serum bicarbonate level was independently associated with
CKD progression after the adjustment for patient character-
istics. Second, in this study, the population included
patients treated and untreated with sodium bicarbonate.
The proportion of sodium bicarbonate use and the dose of
sodium bicarbonate were higher in the low-bicarbonate
group than in the control group. The sample size was not
large enough to analyze the treated and untreated patients
separately. Third, in this study, we examined 113 patients.
The statistical power of this study may not be sufficient for
detecting the relationship between laboratory variables and
CKD progression. Fourth, the number of censored observa-
tions was high. The main reason for censoring was the
change of hospital. Selection and geographical biases may
have been included in this study. Fifth, acidosis-related
markers such as arterial blood gas, arterial pH, and en-
dogenous acid production were not measured. We were
unable to investigate the determinants of the low serumbicarbonate levels that may contribute to CKD progression.
Sixth, CKD-mineral-bone-disease-related markers, such as
serum calcium, phosphate, and parathyroid hormone levels,
were not measured. Therefore, we were unable to evaluate
the relationship between serum bicarbonate level and bone
metabolism.
Conclusions
Our data showed a possibility that a high serum bicarbon-
ate level within the normal range may more effectively pre-
vent CKD progression in elderly CKD patients, and
suggested that the upper limit of the target serum bicarbon-
ate level may be that of the normal range of serum bicar-
bonate levels. For the prevention of CKD progression, there
are issues that should be resolved: when to start the treat-
ment with sodium bicarbonate and how much sodium bi-
carbonate should be administered. Clinical trials using a
large sample size are required to obtain strong evidence
that can help guide therapies with sodium bicarbonate.
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